Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Q4 2019 Earnings Conference Call March 12, 2020 8:30 AM ET
Company Participants
Allen Baharaff - Chairman, CEO & President
Yohai Stenzler - CFO & Controller
Liat Hayardeny - Chief Scientific Officer
Conference Call Participants
Yasmeen Rahimi - ROTH Capital Partners
Steven Seedhouse - Raymond James
Antonio Arce - H.C. Wainwright & Co.
Kristen Kluska - Cantor Fitzgerald
Jason McCarthy - Maxim Group
Operator
Good day, and welcome to Galmed’s Fourth Quarter and Full Year 2019 Conference Call. Today's conference is being recorded.
Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs, as well as other statements that relate to future events. These statements are based on the beliefs and expectations of management as of today, and actual results, trends, timelines and projections relating to our financial position and projected development programs, and pipeline could differ materially.
We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitation, the risks under heading Risk Factors, described in our Annual Report on Form 20-F filed with the SEC, and the risks and uncertainties included in the Form 6-K filed with the SEC earlier today. Galmed assumes no obligation to update any forward-looking statements or information, which speak as of the respective dates only.
I would now like to turn the call over to Allen Baharaff, President and Chief Executive Officer. Allen, please go ahead.
Allen Baharaff
Good morning. And thank you for joining us on today's conference call. I'm pleased to be here today with our Chief Scientific Officer, Dr. Liat Hayardeny; and our Chief Financial Officer, Yohai Stenzler, to provide you with an update on
- Read more current GLMD analysis and news
- View all earnings call transcripts